Accelerating the Discovery of a Bispecific Antagonist Using AI/ML and High-Throughput Screening
- Learn how Alloy’s modular, fully human Common Light Chain (ATX-CLC) platform accelerates bispecific antibody discovery
- Hear how we rapidly identified leads with high-yield expression, optimal pairing, and streamlined functional validation.
- See how this approach enabled the creation of a potent dual antagonist bispecific targeting two distinct pathways.